Equillium, Inc.
NASDAQ:EQBiotechnology
Healthcare
$1.12 +1.51%
+$0.05 today
- Market cap
- $92.20M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
52W Low $0.27High $3.45
Volume 0.60M
Average 0.60M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$22.75M
FY 2025 · Annual
Investing Cash Flow
$4.46M
FY 2025 · Annual
-67.7% YoYFinancing Cash Flow
$30.43M
FY 2025 · Annual
+18453.0% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (39.05M) | (62.43M) | (13.34M) | (8.07M) | (22.4M) |
| Depreciation & Amortization | 72K | 118K | 126K | 137K | 116K |
| Deferred Income Tax | 554K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.41M | 4.84M | 4M | 3.75M | 2.32M |
| Change in Working Capital | 1.7M | 19K | (2.55M) | 842K | (2.32M) |
| Accounts Receivables | 0 | (2.84M) | (897K) | 3.74M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.58M) | 2.51M | 723K | (2M) | (1.94M) |
| Other Working Capital | 3.28M | 349K | (2.37M) | (898K) | (380K) |
| Other Non-Cash Items | 237K | 48.72M | (10.03M) | (15.69M) | (469K) |
| Operating Cash Flow | (32.08M) | (8.73M) | (21.78M) | (19.03M) | (22.75M) |
| Capital Expenditures | (57K) | (279K) | (50K) | (85K) | (48K) |
| Acquisitions (Net) | 0 | 700K | 0 | 0 | 12K |
| Purchases of Investments | (32.99M) | (14.96M) | (54.71M) | (17.6M) | 0 |
| Sales of Investments | 60.46M | 33.23M | 50M | 31.5M | 4.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 27.41M | 18.68M | (4.76M) | 13.81M | 4.46M |
| Debt Repayment | 0 | (1.43M) | (9.13M) | 0 | 0 |
| Common Stock Issued | 29.91M | 214K | 0 | 164K | 30.43M |
| Common Stock Repurchased | 0 | 0 | (260K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.15M | 0 | 165K | 0 | 0 |
| Financing Cash Flow | 31.06M | (1.22M) | (9.23M) | 164K | 30.43M |
| Effect of Forex Changes | (2K) | 5K | (118K) | (83K) | 47K |
| Net Change in Cash | 26.38M | 8.74M | (35.89M) | (5.13M) | 12.19M |
| Free Cash Flow | (32.14M) | (9.01M) | (21.83M) | (19.11M) | (22.79M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$22.4M
+ D&A$116.0K
+ Stock-Based Comp$2.3M
+ Deferred Tax$0
- Working Capital-$2.3M
- Other Non-Cash-$469.0K
= Operating Cash Flow-$22.7M
- Capex-$48.0K
= Free Cash Flow-$22.8M
Analysis
FY2025 free cash flow is -$22.8M. FCF conversion is 101.8% of net income. Operating cash flow was -$22.7M, with capex of -$48.0K. The largest bridge item is Stock-Based Comp at $2.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| S-3 | S-3 filing | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 12, 2026 |
Does EQ generate free cash flow?
Equillium, Inc. (EQ) generated -$22.79M of free cash flow in fiscal 2025.
How much operating cash flow does EQ produce?
Operating cash flow was -$22.75M, before capital expenditures of $48,000.00.
Continue the stock analysis
Jump to another research area for this company.